This study was approved by the Ethics Committee of Nanjing Drum Tower Hospital (No. 2018-160-02) and registered in the Chinese Clinical Trial Registry (ChiCTR2100054057, https://www.chictr.org.cn , June 5, 2022; Yan Wang, M D.). Clinical trial procedures followed the principles of the Declaration of Helsinki.
A total of 132 patients with lung nodules receiving VATS with general anesthesia (the GA Group), ultrasound-guided RIB (RIB Group), or PVB (the PVB Group) in the plane of the T5 level using 0.4% ropivacaine (Zhejiang Xianju Pharmaceutical Co., Ltd., Zhejiang, China) at 3 mg/kg between June 8th, 2022, and August 10th, 2022, were recruited.
Inclusion criteria are as follows: (1) 18–80 years of age; (2) American Society of Anesthesiologists (ASA) Class I-III; and (3) written informed consent was obtained.
Exclusion criteria are as follows: (1) Allergy to local anesthetics, nonsteroidal anti-inflammatory drugs, and opioids; (2) infection of the skin at the puncture site; (3) peptic ulcer disease or inflammatory bowel disease; (4) renal deficiency; (5) transferring to thoracotomy; (6) daily use of opioids; and (7) bilateral operation.
A total of 132 patients with lung nodules receiving VATS with general anesthesia (the GA Group), ultrasound-guided RIB (RIB Group), or PVB (the PVB Group) in the plane of the T5 level using 0.4% ropivacaine (Zhejiang Xianju Pharmaceutical Co., Ltd., Zhejiang, China) at 3 mg/kg between June 8th, 2022, and August 10th, 2022, were recruited.
Inclusion criteria are as follows: (1) 18–80 years of age; (2) American Society of Anesthesiologists (ASA) Class I-III; and (3) written informed consent was obtained.
Exclusion criteria are as follows: (1) Allergy to local anesthetics, nonsteroidal anti-inflammatory drugs, and opioids; (2) infection of the skin at the puncture site; (3) peptic ulcer disease or inflammatory bowel disease; (4) renal deficiency; (5) transferring to thoracotomy; (6) daily use of opioids; and (7) bilateral operation.
Free full text: Click here
